Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

30.90USD
19 Jan 2018
Change (% chg)

$0.35 (+1.15%)
Prev Close
$30.55
Open
$30.89
Day's High
$31.32
Day's Low
$30.45
Volume
48,531
Avg. Vol
40,567
52-wk High
$32.74
52-wk Low
$16.98

Chart for

About

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocyt... (more)

Overall

Beta: --
Market Cap(Mil.): $714.42
Shares Outstanding(Mil.): 25.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

03 Jan 2018

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW

27 Nov 2017

BRIEF-Dova Pharmaceuticals reports third quarter results

* Dova Pharmaceuticals reports third quarter 2017 operating and financial results

09 Nov 2017

BRIEF-Dova Pharmaceuticals announces New Drug Application submission to FDA

* Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist

22 Sep 2017

BRIEF-Dova Pharmaceuticals qtrly net loss per share, basic and diluted $0.32

* Dova Pharmaceuticals reports second quarter 2017 operating and financial results

10 Aug 2017

BRIEF-Perceptive Advisors reports 6.8 pct passive stake in Dova Pharma

* Perceptive Advisors Llc reports a 6.8 pct passive stake in Dova Pharmaceuticals Inc as of July 5 - SEC filing Source text: (http://bit.ly/2uQUtT6)

01 Aug 2017

Earnings vs. Estimates